Sentiment-Signal
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 25.07.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensato |
| 18.02.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensato |
| 18.06.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensato |
| 18.03.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensato |
| 15.02.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensato |
| 31.10.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensato |
| 26.04.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensato |
| 31.01.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. (b) |
Stammdaten
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Unternehmen & Branche
| Name | BRISTOL MYERS SQUIBB CO |
|---|---|
| Ticker | BMY |
| CIK | 0000014272 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Drug Manufacturers - General |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 118,50 Mrd. USD |
| Beta | 0,27 |
| Dividendenrendite | 2,50 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 48,194,000,000 | 7,054,000,000 | 3.46 | 90,038,000,000 | 18,473,000,000 |
| 2025-09-30 | 10-Q | 12,222,000,000 | 2,201,000,000 | 1.08 | 96,889,000,000 | 18,552,000,000 |
| 2025-06-30 | 10-Q | 12,269,000,000 | 1,310,000,000 | 0.64 | 94,676,000,000 | 17,435,000,000 |
| 2025-03-31 | 10-Q | 11,201,000,000 | 2,456,000,000 | 1.20 | 92,427,000,000 | 17,389,000,000 |
| 2024-12-31 | 10-K | 48,300,000,000 | -8,948,000,000 | -4.41 | 92,603,000,000 | 16,335,000,000 |
| 2024-09-30 | 10-Q | 11,892,000,000 | 1,211,000,000 | 0.60 | 93,670,000,000 | 17,142,000,000 |
| 2024-06-30 | 10-Q | 12,201,000,000 | 1,680,000,000 | 0.83 | 94,646,000,000 | 17,015,000,000 |
| 2024-03-31 | 10-Q | 11,865,000,000 | -11,911,000,000 | -5.89 | 99,031,000,000 | 16,490,000,000 |
| 2023-12-31 | 10-K | 45,006,000,000 | 8,025,000,000 | 3.86 | 95,159,000,000 | 29,430,000,000 |
| 2023-09-30 | 10-Q | 10,966,000,000 | 1,928,000,000 | 0.93 | 91,263,000,000 | 28,998,000,000 |
| 2023-06-30 | 10-Q | 11,226,000,000 | 2,073,000,000 | 0.99 | 93,489,000,000 | 31,973,000,000 |
| 2023-03-31 | 10-Q | 11,337,000,000 | 2,262,000,000 | 1.07 | 94,281,000,000 | 31,824,000,000 |
| 2022-12-31 | 10-K | 46,159,000,000 | 6,327,000,000 | 2.95 | 96,820,000,000 | 31,061,000,000 |
| 2022-09-30 | 10-Q | 11,218,000,000 | 1,606,000,000 | 0.75 | 98,196,000,000 | 32,671,000,000 |
| 2022-06-30 | 10-Q | 11,887,000,000 | 1,421,000,000 | 0.66 | 100,357,000,000 | 32,600,000,000 |
| 2022-03-31 | 10-Q | 11,648,000,000 | 1,278,000,000 | 0.59 | 103,034,000,000 | 31,580,000,000 |
| 2021-12-31 | 10-K | 46,385,000,000 | 6,994,000,000 | 3.12 | 109,314,000,000 | 35,946,000,000 |
| 2021-09-30 | 10-Q | 11,624,000,000 | 1,546,000,000 | 0.69 | 110,893,000,000 | 37,213,000,000 |
| 2021-06-30 | 10-Q | 11,703,000,000 | 1,055,000,000 | 0.47 | 110,797,000,000 | 36,808,000,000 |
| 2021-03-31 | 10-Q | 11,073,000,000 | 2,021,000,000 | 0.89 | 112,435,000,000 | 37,605,000,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-01 | Elkins David V | Officer, EVP, Chief Financial Officer | Open Market Sale | -4,481 | 62.05 | -278,046.05 | -30,8% | |
| 2026-04-01 | Elkins David V | Officer, EVP, Chief Financial Officer | Open Market Sale | -25,519 | 61.60 | -1,571,970.40 | -173,9% | |
| 2025-09-02 | Elkins David V | Officer, EVP, Chief Financial Officer | Open Market Sale | -56,000 | 47.33 | -2,650,480.00 | -293,1% | |
| 2025-08-02 | Short Bartie Wendy | Officer, EVP, Corporate Affairs | Open Market Sale | -378 | 44.23 | -16,718.94 | -1,8% | |
| 2025-05-09 | Hickey Benjamin | Officer, President, RayzeBio Org. | Open Market Sale | -97 | 38.01 | -3,701.83 | -0,4% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.